Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis

Documenti analoghi

• Cost‐effectiveness of fenfluramine as add‐on treatment in the management of Dravet Syndrome: A real‐world multicenter study
  di: Paolo A. Cortesi, et al.
  Pubblicazione: (2025)
• Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
  di: Elaine C. Wirrell, et al.
  Pubblicazione: (2024)
• Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach
  di: J. Helen Cross, et al.
  Pubblicazione: (2026)
• Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
  di: Han Wang, et al.
  Pubblicazione: (2025)
• Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program
  di: Arie Weinstock, et al.
  Pubblicazione: (2024)